Jiubing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiubing Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Xingyao Bu
Department of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, China
3 shared publications Meiyun Wang
Department of Radiology Zhengzhou University People's Hospital Henan University People's Hospital Henan Provincial People's Hospital Zhengzhou China
2 shared publicationsRuijiao Zhao
Department of Pathology Henan Provincial People's Hospital Zhengzhou China
2 shared publicationsYushuai Gao
Department of Neurosurgery Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province Glioma Clinical Diagnosis and Treatment Center of Henan Province Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou China
2 shared publicationsZhaoyue Yan
Department of Neurosurgery Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province Glioma Clinical Diagnosis and Treatment Center of Henan Province Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou China
2 shared publicationsZiyue Zhang
Department of Neurosurgery Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province Glioma Clinical Diagnosis and Treatment Center of Henan Province Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou China
2 shared publications
Latest Publications
Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial
Background: This study evaluated tislelizumab combined with low‐dose bevacizumab in recurrent glioblastoma (rGBM), assessing efficacy, safety, and mechanisms of immune escape. Methods: This randomized phase 2 trial divided patients into treatment arms with distinct strategies. Longitudinal tumor in situ fluid (TISF) samples were collected for molecular analysis to monitor genome evolution. Immunohistochemical markers in paired primary and recurrent tumor specimens were analyzed to assess therapy‐induced immune resistance. Results: A total of 109 patients were included, with 59 in the control group and 50 in the experimental group. No grade 4 adverse events or treatment discontinuations occurred in the experimental group. The experimental group demonstrated a median overall survival of 13.3 months, compared to 6.6 months in the control group. The objective response rate and disease control rate were 32.6% and 79.1%, respectively. Post‐treatment TISF analysis revealed a 68.4% reduction in detectable genomic alterations. Immunophenotypic analysis of paired tumor samples showed increased infiltration of CD163 + macrophages and elevated GDF‐15 expression in recurrent tumors. Conclusion: This study shows that combining tislelizumab and low‐dose bevacizumab improves survival in rGBM patients with good safety and tolerability. Dynamic changes in TISF‐based molecular markers reflect genomic evolution and predict prognosis. Increased CD163 + cell infiltration in recurrent tumors may activate M2 macrophages, promoting tumor growth and immune evasion. Elevated GDF‐15 levels may further suppress antitumor immunity, facilitating immune escape.
Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial
Background: This study evaluated tislelizumab combined with low‐dose bevacizumab in recurrent glioblastoma (rGBM), assessing efficacy, safety, and mechanisms of immune escape. Methods: This randomized phase 2 trial divided patients into treatment arms with distinct strategies. Longitudinal tumor in situ fluid (TISF) samples were collected for molecular analysis to monitor genome evolution. Immunohistochemical markers in paired primary and recurrent tumor specimens were analyzed to assess therapy‐induced immune resistance. Results: A total of 109 patients were included, with 59 in the control group and 50 in the experimental group. No grade 4 adverse events or treatment discontinuations occurred in the experimental group. The experimental group demonstrated a median overall survival of 13.3 months, compared to 6.6 months in the control group. The objective response rate and disease control rate were 32.6% and 79.1%, respectively. Post‐treatment TISF analysis revealed a 68.4% reduction in detectable genomic alterations. Immunophenotypic analysis of paired tumor samples showed increased infiltration of CD163 + macrophages and elevated GDF‐15 expression in recurrent tumors. Conclusion: This study shows that combining tislelizumab and low‐dose bevacizumab improves survival in rGBM patients with good safety and tolerability. Dynamic changes in TISF‐based molecular markers reflect genomic evolution and predict prognosis. Increased CD163 + cell infiltration in recurrent tumors may activate M2 macrophages, promoting tumor growth and immune evasion. Elevated GDF‐15 levels may further suppress antitumor immunity, facilitating immune escape.
- Open Access
- 5 March 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 97 (3) , 671-680
Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas
BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) recurrence after surgery remains a significant clinical challenge because of limited early detection methods and effective molecular markers. This study investigates the potential of dynamic tumor in situ fluid circulating tumor DNA (TISF-ctDNA) as a tool for monitoring molecular residual disease and evaluating treatment efficacy in postsurgical patients with GBM. METHODS: In this prospective cohort study, 75 resectable glioma patients were enrolled between October 2019 to June 2023. Primary tumor tissues and postsurgical TISF samples were collected, along with cranial imaging. TISF-ctDNA was identified through targeted next-generation sequencing, with positivity defined by the presence of one or more variants in the TISF matching those of the primary tumors or an increase of ≥10 single-nucleotide variants across consecutive assessments. RESULTS: TISF-ctDNA positivity was identified in 62.2% of patients in the early postsurgical period, indicating a high prevalence of molecular residual disease. Patients with positive TISF-ctDNA showed a significantly higher risk of recurrence (hazard ratio 2.512, 95% CI 1.264-4.993, P = .0054). Conversion to TISF-ctDNA negativity post-treatment was associated with improved overall survival, highlighting its role in evaluating treatment response. Multivariate analysis revealed that TISF-ctDNA positivity was an independent predictor of progression-free survival during adjuvant therapy, with high predictive accuracy (sensitivity 86.2%, specificity 100%). Importantly, TISF-ctDNA positivity preceded imaging signs of recurrence by a median of 71 days. In this study, no significant impact of specific tumor markers in each subcohort (EGFR, TP53, PTEN, NF1) on progression-free survival or overall survival was observed. CONCLUSION: TISF-ctDNA is a promising biomarker for monitoring GBM recurrence and evaluating clinical benefit. It provides insight into tumor genomic evolution and identifies patients who may benefit from adjuvant chemotherapy. TISF-ctDNA positivity is a robust prognostic indicator for patient outcomes and a marker for molecular recurrence after frontline therapy.
- 5 March 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 97 (3) , 671-680
Open AccessDynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas
BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) recurrence after surgery remains a significant clinical challenge because of limited early detection methods and effective molecular markers. This study investigates the potential of dynamic tumor in situ fluid circulating tumor DNA (TISF-ctDNA) as a tool for monitoring molecular residual disease and evaluating treatment efficacy in postsurgical patients with GBM. METHODS: In this prospective cohort study, 75 resectable glioma patients were enrolled between October 2019 to June 2023. Primary tumor tissues and postsurgical TISF samples were collected, along with cranial imaging. TISF-ctDNA was identified through targeted next-generation sequencing, with positivity defined by the presence of one or more variants in the TISF matching those of the primary tumors or an increase of ≥10 single-nucleotide variants across consecutive assessments. RESULTS: TISF-ctDNA positivity was identified in 62.2% of patients in the early postsurgical period, indicating a high prevalence of molecular residual disease. Patients with positive TISF-ctDNA showed a significantly higher risk of recurrence (hazard ratio 2.512, 95% CI 1.264-4.993, P = .0054). Conversion to TISF-ctDNA negativity post-treatment was associated with improved overall survival, highlighting its role in evaluating treatment response. Multivariate analysis revealed that TISF-ctDNA positivity was an independent predictor of progression-free survival during adjuvant therapy, with high predictive accuracy (sensitivity 86.2%, specificity 100%). Importantly, TISF-ctDNA positivity preceded imaging signs of recurrence by a median of 71 days. In this study, no significant impact of specific tumor markers in each subcohort (EGFR, TP53, PTEN, NF1) on progression-free survival or overall survival was observed. CONCLUSION: TISF-ctDNA is a promising biomarker for monitoring GBM recurrence and evaluating clinical benefit. It provides insight into tumor genomic evolution and identifies patients who may benefit from adjuvant chemotherapy. TISF-ctDNA positivity is a robust prognostic indicator for patient outcomes and a marker for molecular recurrence after frontline therapy.
- Open Access
- 1 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (5) , e70733
Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study
Background: Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile and clonal evolution of gliomas with different recurrence patterns. To investigate the value of ctDNA in predicting early postoperative tumor recurrence and guiding prognosis stratification in patients with glioma.Methods: We prospectively recruited 92 patients with near‐total resection of gliomas from our center. Two hundred and thirty‐four postoperative tissue and Tumor In Situ Fluid (TISF) samples from 69 eligible patients were included in ctDNA analysis.Results: Among the 69 patients, 37 glioblastoma (GBM) patients experienced recurrence, and the median progression‐free survival (mPFS) was not significantly different between the situ recurrence group and the non‐in situ recurrence group (8.6 vs. 6.1 months). The ctDNA of recurrent tissue and TISF were significantly consistent. Before and after initial treatment, TISF‐ctDNA mutant allele fraction (MAF), subclonal mutation, and alterations in related pathways (lysine degradation and PI3K pathway) were negatively correlated with treatment response and PFS. Among recurrent GBM patients, EGFR mutations were the most common. Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM.Conclusions: In glioma patients undergoing primary surgery, dynamic monitoring of ctDNA and genotyping can be used for early risk stratification, efficacy monitoring, and early recurrence detection, and provide a basis for clinical research to evaluate early therapeutic intervention.
- 1 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (5) , e70733
Open AccessDynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study
Background: Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile and clonal evolution of gliomas with different recurrence patterns. To investigate the value of ctDNA in predicting early postoperative tumor recurrence and guiding prognosis stratification in patients with glioma.Methods: We prospectively recruited 92 patients with near‐total resection of gliomas from our center. Two hundred and thirty‐four postoperative tissue and Tumor In Situ Fluid (TISF) samples from 69 eligible patients were included in ctDNA analysis.Results: Among the 69 patients, 37 glioblastoma (GBM) patients experienced recurrence, and the median progression‐free survival (mPFS) was not significantly different between the situ recurrence group and the non‐in situ recurrence group (8.6 vs. 6.1 months). The ctDNA of recurrent tissue and TISF were significantly consistent. Before and after initial treatment, TISF‐ctDNA mutant allele fraction (MAF), subclonal mutation, and alterations in related pathways (lysine degradation and PI3K pathway) were negatively correlated with treatment response and PFS. Among recurrent GBM patients, EGFR mutations were the most common. Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM.Conclusions: In glioma patients undergoing primary surgery, dynamic monitoring of ctDNA and genotyping can be used for early risk stratification, efficacy monitoring, and early recurrence detection, and provide a basis for clinical research to evaluate early therapeutic intervention.